Aurinia Pharmaceuticals Inc., of Victoria, British Columbia, sold about 2.3 million common shares at a weighted average price of $6.40 each under its previously announced open sales agreement, which grossed the company approximately $15 million. At this time, Aurinia doesn't have plans to sell more shares in the at-the-market offering.